In Vivo RNAi – Considerations and Examples; a Panel Presentation

Panelists: Dr Garret Rettig and Pascal Tétreault

In Vivo RNAi – Considerations and Examples; a Panel Presentation

Advancing RNAi experiments towards in vivo studies represents a more rigorous level of testing for nucleic acid therapeutics beyond in vitro, cell-based experiments.  Dr Garrett Rettig presents considerations for producing significant knockdown, including:

  • A suitable model system for testing gene knockdown or phenotypic effect
  • Route of delivery
  • Delivery vehicle
  • Potential for off-target effects
Then, Pascal Tétreault presents an example of an in vivo RNAi application, along with a description of the logistics of in vivo experiments conducted in Dr Philippe Sarret’s pre-clinical pain lab. The lab uses DsiRNA silencing technology to study the mechanisms of action of G protein-coupled receptors involved in chronic pain in the spinal cord.

Both Dr Rettig and Tétreault then discuss challenges for in vivo RNAi experimental setup and take questions from the audience.

Webinar Q & A

Garret Rettig Garret Rettig, PhD
Dr Garrett Rettig is a Research Scientist in Molecular Genetics at IDT. He has a PhD in Pharmacy – Medicinal Chemistry from the University of Iowa where he studied synthetic peptide delivery systems for plasmid DNA and siRNA both in vitro and in vivo. At IDT, Dr Rettig has been involved in high-throughput screening of siRNAs in vitro, and has recently co-authored a comprehensive review on siRNA in vivopublished in Molecular Therapy.
Pascal Tétreault
Pascal Tétreault is a senior Ph.D student in neuroscience in the laboratory of Dr Philippe Sarret at the Université de Sherbrooke, Canada, with a focus on the implication of neurotensin receptors in chronic neuropathic pain. His collaboration with the IDT research team and DsiRNA technology has resulted in his co-authoring two book chapters on the use of RNAi in vivo in a chronic pain system.